is semaglutide shortage over The Ozempic Out of Shortage, Into Controversy:

Results May Vary: Individual responses to GLP-1 medications vary significantly

Being overweight or obese is a serious health problem connected with some leading causes of death, including diabetes, stroke, and heart disease, and is associated with an increased risk of certain types of cancer

The dual-agonist approach appears to produce greater glycemic control and weight reduction compared to selective GLP-1 receptor agonists in clinical trials

For patients with type 2 diabetes and obesity, prescribing the diabetes-indicated formulation may encounter fewer coverage barriers while achieving the same weight loss benefits

however, its effect on skin physiology remains speculative and unconfirmed in published human clinical data